 Connection
Paul Bunn to Disease Models, Animal
This is a "connection" page, showing publications Paul Bunn has written about Disease Models, Animal.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.132 |
|
|
|
-
Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016 10; 15(10):2314-2322.
Score: 0.070
-
Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):37-46.
Score: 0.025
-
Bunn PA, Chan DC, Earle K, Zhao TL, Helfrich B, Kelly K, Piazza G, Whitehead CM, Pamukcu R, Thompson W, Alila H. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 4):87-94.
Score: 0.025
-
Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 2005 Dec; 167(6):1763-75.
Score: 0.008
-
Mulvin DW, Howard RB, Mitchell DH, Noker PE, Kruse CA, Chu HD, Bunn PA, Johnston MR. Secondary screening system for preclinical testing of human lung cancer therapies. J Natl Cancer Inst. 1992 Jan 01; 84(1):31-7.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|